Connect with us

Health

CEPI begins first human trial of Bundibugyo Ebola vaccine

info

Published

on

Ebola has killed 69 guinea january.jpg

MTN ADVERT

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced the start of the world’s first human clinical trial of a vaccine developed specifically against the Bundibugyo strain of the Ebola virus, with the first volunteer vaccinated at the University of Oxford.

The announcement was contained in a statement made available to the News Agency of Nigeria (NAN) on Friday by CEPI’s Senior Communications and Advocacy Manager, Jodie Rogers.

The Phase I clinical trial, known as BD-Ebov, will evaluate the safety of the experimental vaccine and its ability to stimulate immune responses in healthy adult volunteers.

The vaccine candidate, ChAdOx1 BDBV, was developed by scientists at the University of Oxford’s Oxford Vaccine Group and the Pandemic Sciences Institute using the same adenoviral vector technology employed in the Oxford/AstraZeneca COVID-19 vaccine.

According to the statement, the milestone comes only weeks after the launch of the BD-Ebov study and marks the first time the ChAdOx1 BDBV vaccine has been administered to humans.

PT WHATSAPP CHANNEL

It said the vaccine development programme had progressed rapidly through collaboration among the University of Oxford, its Clinical BioManufacturing Facility, the Serum Institute of India (SII) and CEPI.

The statement added that SII manufactured the vaccine candidate in record time and has stockpiled approximately 620,000 doses, while providing 4,000 investigational doses for the ongoing clinical trial.

CEPI said the trial forms part of an $8.6 million programme supporting the University of Oxford and SII to accelerate the development of a vaccine against the Bundibugyo strain.

Ebola outbreak

NAN reports that the trial comes as the Democratic Republic of the Congo (DRC) battles a severe outbreak of Bundibugyo Ebola Virus Disease, with more than 2,500 confirmed cases and over 1,000 deaths recorded.

Unlike the Zaire strain of Ebola, for which licensed vaccines are available, there is currently no approved vaccine specifically targeting the Bundibugyo strain.

David Pulido-Gomez, Global Chemistry, Manufacturing and Controls Lead at the Pandemic Sciences Institute, said the vaccine candidate moved from concept to clinical evaluation within just eight weeks.

“Reaching this milestone in such a short timeframe reflects an extraordinary collaborative effort,” he said.

“Working alongside colleagues at the Clinical BioManufacturing Facility and the Serum Institute of India, we have taken this vaccine candidate from concept to clinic in just eight weeks.”

The Lead Study Doctor, Peter Skydmore, described the vaccination of the first participant as a significant milestone.

Mr Skydmore said while these are very early days, they represent an important first step in evaluating this vaccine in humans.

“Over the coming months, we will continue vaccinating and monitoring participants while assessing the vaccine’s safety and immune responses,” he said.

Chief Investigator, Katrina Pollock, said the commencement of the trial marked another important phase in the multinational effort to develop a vaccine against the Bundibugyo ebolavirus.

Ms Pollock commended the commitment of research partners and volunteers, saying their participation was critical to responding to the ongoing outbreak.

Commenting on the development, CEPI Chief Executive Officer, Richard Hatchett, said the worsening outbreak in the DRC underscored the urgency of developing a vaccine against the Bundibugyo strain.

“With Bundibugyo cases increasing at a concerning rate in the DRC, this epidemic shows no signs of stopping,” he said.

“The need for a vaccine against this specific Ebolavirus becomes more urgent every day.”

Also speaking, Chief Executive Officer of SII, Adar Poonawalla, said the rapid manufacture of the vaccine candidate demonstrated how scientific innovation and scalable production could accelerate responses to emerging infectious diseases.

He reaffirmed the institute’s commitment to supporting equitable access to vaccines for populations most at risk.

According to the statement, recruitment and vaccination of additional volunteers will continue over the coming weeks, while preparations are underway, subject to regulatory approval, for further clinical studies in Uganda.

It added that if the Phase I trial demonstrates favourable safety and immune responses, CEPI, the University of Oxford and SII will advance to larger late-stage studies to support emergency use authorisation or full regulatory approval.

ALSO READ: Ebola: BVD outbreak in DRC remains active with 2,124 cases

The partners also pledged to ensure the rapid, affordable and equitable supply of the vaccine to affected countries once it is successfully developed.

About the vaccine

NAN reports that ChAdOx1 BDBV is an experimental vaccine developed specifically to protect against the Bundibugyo strain, one of the species that causes Ebola Virus Disease.

The vaccine uses the ChAdOx1 platform, a harmless chimpanzee adenovirus vector engineered to carry genetic material from the Bundibugyo ebolavirus.

The technology trains the body’s immune system to recognise and fight the virus without causing Ebola infection.

The same ChAdOx1 platform was used to develop the Oxford/AstraZeneca COVID-19 vaccine, which was deployed globally during the COVID-19 pandemic.

Researchers say the existing platform enabled the rapid development of the Bundibugyo vaccine candidate. (NAN)


Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

PT Health Watch: How Pregnancy-Induced Hypertension puts mother, baby at risk

info

Published

on

Pregnant.jpeg

High blood pressure during pregnancy can put both the mother and baby at risk, if not detected and properly managed.

Pregnancy-induced hypertension (PIH) is high blood pressure that develops during pregnancy, usually after the first half of pregnancy. It can also progress to more severe hypertensive disorders, including pre-eclampsia.

A 2024 study, titled: “Prevalence and determinants of hypertensive disorders of pregnancy in Nigeria: a multi-centre study,” involving 71,758 women across 54 referral-level health facilities in Nigeria found that 6.4 per cent had hypertensive disorders of pregnancy.

Gestational hypertension accounted for 49.8 per cent of the cases, while pre-eclampsia and eclampsia accounted for 9.5 per cent and seven per cent respectively.

Speaking with PT Health Watch, Lewis Aituma, a Consultant Obstetrician and Gynaecologist, University of Benin Teaching Hospital, said pregnancy-induced hypertension is a major contributor to poor pregnancy outcomes for both mother and child.

Causes of PIH

Mr Aituma said there is no known single cause of the condition, but several factors can increase a woman’s risk.

PT WHATSAPP CHANNEL
Dangote Refinery AD

He listed previous PIH, first pregnancy, advanced maternal age, diabetes, kidney disease, a long interval between pregnancies, family history of hypertension, multiple pregnancy and obesity among the risk factors.

The Nigerian study also found that women above 35 years, women who had never given birth, women with several previous births and those with a previous caesarean section or miscarriage had increased odds of developing hypertensive disorders of pregnancy.

Watch out for warning signs

Mr Aituma advised pregnant women to have their blood pressure checked routinely and watch for rising values.

He said women should also report persistent headaches, blurred vision, a feeling of abnormal heartbeat, chest pain and rapidly increasing swelling of the legs.

“Such symptoms should warrant an emergency presentation to the Obstetrician for expert evaluation and management,” he said.

However, some women with pregnancy-related hypertension may have no obvious symptoms, making regular antenatal checks important.

The World Health Organisation (WHO) recommends monitoring blood pressure during pregnancy because early detection and treatment of hypertensive disorders can help prevent serious complications.

How it affects mother, baby

When PIH is not identified and properly managed, Mr Aituma said it can progress to pre-eclampsia and cause serious complications for the mother, including eclampsia, seizures, stroke and kidney failure.

For the baby, he said it can increase the risk of premature birth, poor fetal growth, fetal death and premature separation of the placenta.

The Nigerian study found that 11.9 per cent of pregnancies affected by hypertensive disorders ended in stillbirth, while 3.7 per cent of women with the disorders died.

The researchers concluded that hypertensive disorders of pregnancy remain an important health concern in Nigeria.

WHO also identifies preterm birth, restricted fetal growth, placental abruption and maternal or fetal death among possible complications of severe hypertensive disorders in pregnancy.

Managing the condition

Mr Aituma said treatment depends on the severity of the condition and how far the pregnancy has progressed.

“For less severe forms, effort will be geared to blood pressure control and prevention of complications till the pregnancy is delivered,” he said.

He explained that where the pregnancy is still early, doctors may try to safely prolong it, while at later gestational ages, “the emphasis is to conduct a delivery.”

For severe cases, the priority is to control the woman’s blood pressure, prevent seizures and deliver the baby when necessary.

WHO also recommends close monitoring, blood pressure treatment and timely delivery where required, depending on the severity of the condition and gestational age.

READ ALSO: Pregnant woman allegedly dies at Ondo fake medical facility

Reducing the risk

Mr Aituma said maintaining a healthy weight, exercising, making appropriate lifestyle changes and attending regular antenatal appointments can help reduce the risk of complications.

He also advised pregnant women to monitor their blood pressure regularly and report any concerning symptoms promptly.

“Overall, prognosis is good in early diseases. Women should watch out for common symptoms in pregnancy and report the same promptly to their Obstetrician for action, Mr Aituma noted.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading

Health

Nigeria demands fairer pandemic financing, vaccine access at UN meeting

info

Published

on

C1FF02CE A189 4990 B78C 93328E299EA3 e1790449952798.png

Nigeria has called for a more equitable global pandemic preparedness system, urging increased financing, technology transfer and stronger manufacturing capacity in Africa to enable developing countries to respond effectively to future health emergencies.

The Minister of State for Health and Social Welfare, Iziaq Salako, made the call while delivering Nigeria’s national statement on behalf of President Bola Tinubu at a high-level meeting on Pandemic Prevention, Preparedness and Response (PPPR) at the United Nations Headquarters in New York.

The meeting was held on the sidelines of the 81st United Nations General Assembly.

Mr Salako said effective pandemic preparedness must begin with strong public health systems capable of preventing, detecting and responding to health threats before they become emergencies.

“Prevention is preparedness and the strength of everyday public health systems determines how effectively nations detect threats early, respond rapidly, and maintain essential services during crises,” he said.

He said Nigeria was strengthening its legal and institutional frameworks, expanding digital disease surveillance, institutionalising the 7-1-7 approach, enhancing genomic sequencing capacity and improving multi-hazard preparedness.

PT WHATSAPP CHANNEL
Dangote Refinery AD

The 7-1-7 approach requires countries to aim to detect a suspected public health threat within seven days, notify the relevant authorities within one day and complete the initial response within seven days.

Greater equity

Mr Salako said equity must remain central to the global PPPR agenda, particularly in ensuring that countries that provide access to pathogens receive fair and timely benefits from the development of vaccines, diagnostics and therapeutics.

He called for sustainable and rapidly accessible financing for low- and middle-income countries, alongside technology transfer and stronger domestic manufacturing capacity, particularly in Africa.

Nigeria’s priorities, he said, include stronger national ownership, governance and legal preparedness; prevention-focused health systems; integrated and resilient One Health systems; equitable access to financing and African manufacturing; and greater regional and global solidarity and accountability.

“National ownership and global solidarity must advance together,” he said.

Mr Salako said Nigeria was also advancing the One Health approach, strengthening antimicrobial resistance (AMR) governance and infection prevention and control programmes, and expanding emergency workforce capacity at national and sub-national levels.

The country’s public health laboratory network now covers all 36 states, while Public Health Emergency Operations Centres support responses to outbreaks including Lassa fever, cholera, diphtheria and meningitis, he said.

ALSO READ: Africa’s health-for-all agenda derailed by pandemic, financing gap – Report

Nigeria’s Joint External Evaluation score also improved from 39 per cent in 2017 to 54 per cent in 2023.

In addition, the World Bank’s $250 million Health Security Programme is supporting health security capacity at federal and state levels under a One Health approach, Mr Salako said.

Nigeria to host global AMR meeting

Mr Salako said Nigeria also wanted antimicrobial resistance to remain firmly embedded in the global pandemic preparedness agenda, describing it as “both a current public health threat and a multiplier of pandemic risks”.

Against this background, he announced that Nigeria would host the fifth Global High-Level Ministerial Conference on Antimicrobial Resistance in December 2026.

The conference will be the first edition to be held in Africa and will provide an opportunity to accelerate measurable One Health action and advance the priorities of low- and middle-income countries, he said.

Mr Salako also stressed the importance of involving communities in pandemic preparedness, saying public trust could not be built only after an outbreak had begun.

He called for sustained investment in risk communication and community engagement, social listening, community hygiene and infodemic management between emergencies.

He said Nigeria remained committed to strengthening national and regional capacity to prevent, detect and respond to public health threats, while supporting a global pandemic preparedness framework that is equitable, sustainable and accountable.


Discover more from Premium Times Nigeria

Subscribe to get the latest posts sent to your email.

Continue Reading

Trending